Transforming growth factor alpha and epidermal growth factor levels in bladder cancer and their relationship to epidermal growth factor receptor

British Journal of Cancer

Volumn 73, Issue 5, 1996, Pages 654-658

  Mellon, J K ^a,b   Cook, S ^a   Chambers, P ^a   Neal, D E ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b CITY HOSPITALS SUNDERLAND NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bladder cancer; Epidermal growth factor; Oncogene; Transforming growth factor

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; RADIOLIGAND; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; BLADDER CANCER; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0030064873     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.114     Document Type: Article

References (27)

1. BERGKR MS, GREENFIELD C, GULLICK WJ, HALEY J, DOWNWARD J, NEAL DE, HARRIS AL AND WATERFIELD MD (1987). Evaluation of epidermal growth factor receptors in bladder tumours. Br. J. Cancer, 56, 533-537.
2. BERGKVIST A, LJUNGQVIST A AND MOBERGER G. (1965). Classification of bladder tumours based on the cellular pattern. Acta Chir. Scand., 130, 371-378.
3. CHAUDHARY VK, FITZGERALD DJ, ADHYA S AND PASTAN I. (1987). Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin. Proc. Natl Acad. Sci. USA, 84, 4538-4542.
4. FOX SB, SMITH K, HOLLYER J, GREENALL M, HASTRICH D AND HARRIS AL. (1994). The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res. Treat., 29, 41-49.
5. FUSE H, MIZUNO I, SAKAMOTO M AND KATAYAMA T. (1992). Epidermal growth factor in urine from the patients with urothelial tumours. Urol. Int., 48, 261-264.
6. GAVRILOVIC J, MOENS J, THIERY JP AND JOUANNEAU J. (1990). Expression of transfected transforming growth factor alpha induces a motile fibroblast-like phenotype with extracellular matrix-degrading potential in a rat bladder carcinoma cell line. Cell Regulation, 1, 1003-1014.
7. GREGORY H, THOMAS CK, WILLSHIRE IR, YOUNG JA, ANDERSON H, BAILDAM A AND HOWELL A. (1989). Epidermal and transforming growth factor α in patients with breast tumours. Br. J. Cancer, 59, 605-609.
8. GULLICK WJ, HUGHES CM, MELLON K, NEAL DE AND LEMOINE NR. (1991). Immunohistochemical detection of the epidermal growth factor receptor in paraffin-embedded human tissues. J. Pathol., 164, 285-289.
9. HERMANEK P AND SOBIN LH. (1987). TNM Classification of Malignant Tumours, 4th edn, pp.133. Springer: New York.
10. KAWAMATA H. KAMEYAMA S, NAN L, KAWAI K AND OYASU R. (1993). Effect of epidermal growth factor and transforming growth factor beta I on growth and invasive potentials of newly established rat bladder carcinoma cell lines. Int. J. Cancer, 55, 968-973.
11. KRISTENSEN JK, LOSE G. LUND F AND NEXO E. (1988). Epidermal growth factor in urine from patients with urinary bladder tumours. Eur. Urol., 14, 313-314.
12. LAU JL, FOWLER JK Jr AND GHOSH L. (1988). Epidermal growth factor in the normal and neoplastic kidney and bladder. J. Urol., 139, 170-175.
13. LOWRY OH, ROSEBROUGH NJ, FARR AL AND RANDALL RJ. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193, 265-275.
14. MELLON K, WRIGHT C, KELLY P, HORNE CHW AND NEAL DE. (1995). Long-term outcome related to EGFR status in bladder cancer. J. Urol., 153, 919-925.
15. MESSING E. (1984). Growth factors and human bladder tumors. J. Urol., 131, 111A.
16. MESSING EM, HANSON P, ULRICH P AND ERTURK E. (1987). Epidermal growth factor interactions with normal and malignant urothelium in vivo and in situ studies. J. Urol. 138, 1329 1335.
17. MOMOSE H, KAKINUMA H, SHARIFF SY, MITCHELL GB, RADEMAKER A AND OYASU R. (1991). Tumor-promoting effect of urinary epidermal growth factor in rat urinary bladder carcinogenesis. Cancer Res., 51, 5487-5490.
18. NEAL DE, SMITH K, FENNELLY J, BENNETT MK, HALL RR AND HARRIS AL. (1989). The epidermal growth factor receptor in human bladder cancer: a comparison of immunohistochemistry and radioligand binding. J.Urol., 141, 517-521.
19. NEAL DE, SHARPLES L, SMITH K, FENNELLY J, HALL RR AND HARRIS AL. (1990). The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer, 65, 1619-1625.
20. NICHOLSON S, SAINSBURY JRC, NEEDHAM UK, CHAMBERS P, FARNDON JR AND HARRIS AL. (1988). Quantitative assays of epidermal growth factor receptor in human breast cancer: cut-off points of clinical relevance. Int. J. Cancer. 42, 36-41.
21. SAINSBURY JRC, SHERBERT GV, FARNDON JR AND HARRIS AL (1985). Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet, 1, 364-366.
22. SAMOLS E AND BILKUS D. (1964). A comparison of insulin immunoassays. Proc. Soc. Exp. Biol. Med., 115, 79-84.
23. SAROSDY MF, HUTZLER D AND VON HOFF DD. (1992). TP-40 in bladder cancer: A hybrid protein with selective targeting and cytotoxicity. J. Urol., 147, (supplo), 261A.
24. SAROSDY ME, HUTZLER DH, YEE D AND VON HOFF DD. (1993). In vitro sensitivity testing of human bladder cancers and cell lines to TP-40, a hybrid protein with selective targeting and cytotoxicity. J. Urol., 150, 1950-1955.
25. SMITH K, FENNELLY JA, NEAL DE, HALL RR AND HARRIS AL. (1989). The epidermal growth factor in human bladder cancer: characterization and quantitation of the epidermal growth factor in invasive and superficial bladder tumors. Cancer Res., 49, 5810-5815.
26. VELU TJ. (1990). Stucture, function and transforming potential of the epidermal growth factor receptor. Mol. Cell. Endocrinol., 70, 205-216.
27. WRIGHT C, MELLON K, JOHNSTON P, LANE DP, HARRIS AL, HORNE CHW AND NEAL DE. (1991). Expression of mutant p53, EGFR and c-erbB-2 in transitional cell carcinoma of the human urinary bladder. Br. J. Cancer. 63, 967-970.